drug
as of 2026-07-01Mifepristone
mifepristone
MeSH D015735
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Corcept Therapeutics
7 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
7
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCT00637494Phase 3Terminated
Treatment of Schizoaffective Disorder Using Mifepristone
NCT00725270Phase 2, Phase 3Terminated
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT00128479Phase 3Completed
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
NCT00128505Phase 3Completed
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
NCT00208156Phase 3Completed
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT00146523Phase 3Completed
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT00130676Phase 3Completed
KOLs & investigators
3
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
Treatment of Schizoaffective Disorder Using Mifepristone
trialPHASE2, PHASE3
indication
indication
indication
indication
KOL
Katherine Beebe, PhD
personKOL score —
Thaddeus Block, MD
personKOL score —
Jennifer Keller
personKOL score —